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Edited by Richard MaraisAbstract In a yeast two-hybrid system screen for Cdc42-
interacting proteins, we identiﬁed a protein with similarity to the
CrkII-binding protein DOCK180. A cDNA clone of this protein,
designated DOCK8, encoded a gene-product of 1701 amino acid
residues with a molecular mass of 190 kDa. Immunoﬂuorescence
staining showed that transiently transfected HA-tagged
DOCK8, as well as endogenous DOCK8, was present at the
cell edges in areas undergoing lamellipodia formation. Transient
transfection of a C-terminal fragment of DOCK8 resulted in the
formation of vesicular structures. Interestingly, these vesicles
also contained ﬁlamentous actin. These data suggest an involve-
ment of DOCK8 in processes that aﬀect the organisation of
ﬁlamentous actin.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The Rho GTPases constitute a multi-member group of
proteins, which are pivotal for the morphogenic and migratory
properties of eukaryotic cells [1–3]. These proteins are related
to the proto-oncogenes of the Ras family of small GTPases
and share a substantial amount of the biophysical properties
with Ras [4]. The Rho GTPases bind and hydrolyse GTP and
in this process they cycle between inactive, GDP-loaded, and
active, GTP-loaded, conformations [1]. This ability to alter
conformation is instrumental for the ability of the Rho
GTPases to function as signal transducers and the process is
strictly regulated by guanine-nucleotide exchange factors
(GEFs), GTPase activating proteins (GAPs) and guanine nu-
cleotide dissociation inhibitors (GDIs) [5–7]. Three members
of the Rho GTPases, Cdc42, Rac1 and RhoA, have been ex-
tensively studied and shown to have important roles in regu-
lating the actin ﬁlament system [2]. Current observations
suggest the presence of 22 Rho GTPases in the human genome
and a majority of the additional family members also partici-
pate in cytoskeletal control [3]. In addition, the Rho GTPases
have been shown to regulate critical aspects of cell signalling,
cell growth, cell division and cell survival [8].
A large number of proteins, which bind to the Rho GTP-
ases, have been identiﬁed during the last decade [9,10]. The* Corresponding author. Fax: +46-18-160420.
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doi:10.1016/j.febslet.2004.06.095yeast two-hybrid system and aﬃnity chromatography have
been two successful tools for the identiﬁcation of binding
partners. In search for Cdc42-interacting proteins, employing
the yeast two-hybrid system, we were able to identify seven
Cdc42-binding proteins [11]. In this article, we describe one of
them that showed extensive homology to the Ced-5/
DOCK180/Myoblast City (CDM) family of proteins [12]. This
protein was expressed in a relatively ubiquitous manner in
human tissues. During the course of this study, the CDM-like
proteins identiﬁed by the human genomic sequencing project
were given the name DOCK8, for which reason we refer to this
CDM family member as DOCK8 [13]. Ectopically expressed
DOCK8, as well as endogenous DOCK8 was present in la-
mellipodia and we propose that DOCK8 has a role during the
reorganisation of the actin ﬁlament system.2. Materials and methods
2.1. DNA work and yeast two-hybrid system screen
The Saccharomyces cerevisiae strain Y190 was transformed with
cDNAs encoding Rho GTPases, as depicted in Fig. 3A and B, fused to
the GAL4 DNA-binding domain (GAL4DB) in the pYTH6 vector.
The GAL4DB-Rho GTPase-expressing yeast strains were transformed
with a plasmid encoding a C-terminal fragment of DOCK8
(DOCK8:1044–1701) fused to the GAL4 activation domain
(GAL4AD) in the pACT vector following the previously described
procedure [11].
2.2. DNA work
A human Burkitt lymphoma Daudi cell cDNA library (BD Bio-
sciences) was screened with a DNA fragment derived from the C-ter-
minus of DOCK8. The probe was labelled with Rediprime TM II
Random Prime Labelling System (Amersham Biosciences) according
to the protocol provided by the manufacturer. Hybridisation of the
ﬁlters (Hybond-N+, Amersham Biosciences) followed standard
methods as described in [14]. Clones potentially encoding DOCK8
were subcloned into the pBluescript-SK vector. A second round of
screening was performed with an N-terminal probe. The N-terminus of
DOCK8 was ampliﬁed from the Daudi cell cDNA library as a PCR
product using a 5 prime k and an internal DOCK8 primer. The PCR
product was subcloned using the PCR-Script Amp Cloning Kit
(Stratagene). The full-length DOCK8 cDNA was subcloned into a
HA-tagged pcDNA3 mammalian expression vector. The DNA
sequence analysis was performed on an ABI Prism 310 Genetic
Analyzer.
2.3. Northern blot analysis
A 0.8 kb DNA fragment encoding the C-terminal of DOCK8 was
labelled with [32P]-CTP employing the Rediprime labelling kit
(Amersham Biosciences). The probes were thereafter hybridised to
hybridisation-ready Northern blots (Human Multiple Tissue Northern
Blot, BD Biosciences) according to the ExpressHyb (BD Biosciences)ation of European Biochemical Societies.
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Bioimager.
2.4. GST fusion-protein production and GST pull-down assay
GST fusion proteins of Cdc42, Rac1 and RhoA were puriﬁed as
before and the proteins remained bound to the glutathione–Sepharose
beads [11]. For GST pull-down assays, Cos7 cells were transfected with
plasmids encoding Myc-tagged fragment encoding amino acid residues
495–826 of Dbl, including the DH and PH domains (a generous gift
from M. Olson, The Institute of Cancer Research, London, UK) or a
HA-tagged fragment encoding amino residues 1179–1701 of DOCK8.
GST pull-down assay conditions were essentially adopted from
[11,13,14]. The precipitated material was subjected to Western blotting.
2.5. Cell cultivation, transfection, immunoﬂuorescence
Porcine aortic endothelial cells expressing the human PDGF b-re-
ceptor (PAE/PDGFRb cells), NIH 3T3 and Cos7 cells were cultured as
described before [3,14]. Transfection with LipoFECTAMINE PLUS
(Invitrogen life technologies) and immunoﬂuorescence microscopy
analysis was performed as described before [3]. A peptide encom-
passing amino acid residues 1679–1693 was coupled to KLH and used
to immunise a rabbit to generate a polyclonal DOCK8 antiserum.3. Results
3.1. Cloning of DOCK8
In previous studies, we have reported on a yeast two-hybrid
screen, which identiﬁed seven Cdc42-interacting proteins [11].Fig. 1. Primary structure of DOCK8. (A) Amino acid sequence of DOCK8
marks the CZH1 domain and the second underlined sequence marks the C
DOCK8, encompassing additional 330 amino acid residues. (C) Domain or
DOCK8. (D) Phylogenetic tree representation of the relationship between
method with the PAM250 residue weight table (numbers represent % diverge
DOCK family.A number of independent clones from this screen encoded a
DOCK180-related protein, preliminarily designated DOCK8.
A full-length DOCK8 cDNA of 8 kb, generated by screening a
Daudi cell cDNA library and by PCR ampliﬁcation, encoded a
protein of 1701 amino acid residues (Fig. 1A). Database
searches indicated the presence of alternatively spliced
DOCK8 cDNAs and subsequent sequence analysis showed
that at least one EST clone encoded a DOCK8 cDNA with an
extended 50 end resulting in extra 330 amino acid residues at
the N-terminal part of the protein (Fig. 1B). Previous work has
shown two areas in the CDM proteins with higher degree of
similarity, called CZH-1 and CZH-2 domains (or DHR-1 and
DHR-2) [13,15], the positions of these domains in DOCK8 are
schematically outlined in Fig. 1C. The human CDM family has
11 members, however most of them are still only known from
partial sequences in the public sequence databases. A previous
study divided the CDM proteins in to 4 subfamilies designated
DOCKA, B, C and D [13]. The proteins of DOCKA
(DOCK180, KIAA0299) and B (KIAA0209 (MOCA),
KIAA1706 and DOCK5) are very similar to each other. The
proteins of the DOCKC (DOCK8, KIAA1395 and
KIAA1771) and DOCKD (Zizimin1, DOCK10 and DOCK11)
are also very similar to each other and the similarity is rela-
tively high all over the amino acid sequence (Fig. 1D). How-
ever, the members of DOCKA/B are only marginally similar to
the members of DOCKC/D and the similarity is restricted toencompassing 1701 amino acid residues. The ﬁrst underlined sequence
ZH2 domain. (B) An N-terminal extension in an alternatively spliced
ganisation of the full-length DOCK8 and the C-terminal fragment of
all CZH2 domains of the human DOCK family using the ClustalW
nce). (E) Alignment of the CZH2 domain of all members of the human
Fig. 1 (continued)
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CZH-2 domain with all family members aligned side-by-side).3.2. DOCK8 tissue distribution
Northern blot analysis with a 0.8 kb fragment of the 30
portion of the coding region of DOCK8 showed the expression
of the protein, detected as a single band of 8 kb, in placenta,
lung, kidney and pancreas (Fig. 2A). Low expression of
DOCK8 was furthermore detected in heart, brain and skeletal
muscle. These data implicated that DOCK8 is expressed in a
relatively ubiquitous manner. We also performed Northern
blots with a 50 fragment encoding the N-terminal extension
(see Fig. 1B). In this case, a very weak band of 9 kb, indicative
of a low abundance mRNA, was detected in placenta, lung and
kidney (data not shown).A DOCK8 speciﬁc antiserum was produced by immunising
a rabbit with a peptide derived from the C-terminal of
DOCK8. In order to test the speciﬁcity of the antiserum, dif-
ferent cell-lines were 35S-labelled and DOCK8 was immuno-
precipitated with the DOCK8 speciﬁc antiserum. As a control,
pre-immune serum was employed for immunoprecipitation. A
band with a molecular mass of around 190 kDa was present in
both Burkitt lymphoma Daudi cells as well as in human pro-
myelocytic leukaemia HL-60 cells, consistent with a protein of
1701 amino acid residues (Fig. 2B, arrow). HA-tagged
DOCK8 was transfected into Cos7 cells, the cells were 35S
labelled and HA-DOCK8 was precipitated with the DOCK8
antiserum. A band with a molecular mass of around 190 kDa,
representing ectopopically expressed DOCK8, was visible
(Fig. 2B). No corresponding band was detected in the material
subjected to immunoprecipitation with the pre-immune serum.
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body worked poorly in immunoprecipitation. Taken together,
these observations suggest that the 1701 amino acid residue
protein is the predominant form of DOCK8.Fig. 2. Tissue distribution of DOCK8. (A) Northern blot analysis of DOCK
the DOCK8 mRNA of 8 kb. (B) DOCK8 was precipitated with the DOCK
Cos7 cells transfected with HA-tagged DOCK8 or DOCK8:1179–1701. The a
as well as transfected DOCK8. For unknown reasons, the HA antibody did n
additional band of 60 kDa in Daudi, HL-60 and Cos7 cells, representing eit3.3. Interaction of DOCK8 with Rho GTPases
To study the GTP-dependency of the DOCK8–Cdc42 in-
teraction, one of the plasmids isolated in the yeast two-hybrid
screen (encoding GAL4-AD:DOCK8/1044–1701) was trans-8 mRNA in human tissues, as indicated in the panel. The arrow marks
8-speciﬁc antiserum from lysates of 35S-labelled Daudi, HL-60 cells or
rrow marks the position of the band possibly representing endogenous,
ot work in immunoprecipitation. The asterisk marks the position of an
her a DOCK8-interacting protein or a splice-variant of DOCK8.
Fig. 3. Interaction of DOCK8 with Rho GTPases. (A) Interaction between GAL4AD-DOCK8:1044–1701 with GAL4DB-fusion proteins of
L61Rac1, N17Rac1, L61Cdc42, N17Cdc42, L63RhoA or N19RhoA in the yeast two hybrid system. The colonies were streaked out on plates with
media selecting for the plasmids (Sc–Trp–Leu) or media selecting for a positive interaction (Sc–Trp–Leu–His + 3AT). (B) Interaction between
GAL4AD-DOCK8:1044–1701 with GAL4DB-fusion proteins of L61Cdc42, L75TC10, L77TCL, L89Chp, L107Wrch-1 or L87R-Ras in the yeast
two hybrid system. The colonies were streaked out on plates with media selecting for the plasmids (Sc–Trp–Leu) or media selecting for a positive
interaction (Sc–Trp–Leu–His + 3AT). (C) HA-tagged DOCK8:1179–1701 in precipitates of GST fusion-proteins of Cdc42, Rac1 or RhoA, either
nucleotide free ()) or GTP-loaded (GTP).
A. Ruusala, P. Aspenstr€om / FEBS Letters 572 (2004) 159–166 163formed into yeast strains encoding GAL4-DB fused to
L61Cdc42 or N17Cdc42. The L61 mutant Cdc42 is consti-
tutively in the GTP-bound conformation, whereas the N17
mutant mimics the GDP-bound conformation [16]. DOCK8
bound to L61Cdc42 and N17Cdc42 with the same apparent
aﬃnity (Fig. 3A). DOCK8 bound also to L61Rac1 and
N17Rac1 but not to L63RhoA. In addition, DOCK8 bound
to the Cdc42 family members TCL and TC10 (Fig. 3B).
Next, DOCK8 was tested for binding to Cdc42 in a GST
pull-down assay. GST-Cdc42, GST-Rac1 and GST-RhoA
were either loaded with GTPcS, to generate Rho GTPases
stably in the GTP-bound conformation, or treated with
EDTA to obtain nucleotide-free GTPases. HA-DOCK8/
1179–1701 was transiently transfected into Cos7 cells, the
cells were lysed and the lysates were passed over the gluta-
thione–Sepharose-bound GTPases. In contrast to the yeast
two-hybrid system, we could not detect binding under these
conditions (Fig. 3C). We also made GST fusion-protein of
DOCK8/1179–1701 in Escherichia coli, the proteins were
spotted on nitrocellulose ﬁlters and incubated in the presence
of c32P-GTP-loaded GTPases as has been done for other
Cdc42 binding-partners [11]. We could not ﬁnd a stable
binding to any of the Rho GTPases tested. Moreover, thisGST fusion-protein was not active in any of the GEF (or
GAP) assays performed (data not shown). These observations
might reﬂect that the interaction between DOCK8 and Rho
GTPases is too transient to allow a stable interaction in the
GST pull-down assay. However, it can be noted that a sim-
ilar result was obtained from studies on the DOCK8-related
CDM family member DOCK7, in which a stable interaction
between DOCK7 and Rho GTPases could not be detected
[13].
3.4. Subcellular localisation of DOCK8
In order to examine to subcellular localisation of DOCK8,
PAE/PDGFRb cells were transiently transfected with HA-
tagged DOCK8, the cells were starved and stimulated with
either 100 ng/ml PGDF-BB for 10 min or 10% FCS for 5 min.
The cells were ﬁxed and HA-DOCK8 was visualised with HA-
speciﬁc antibodies followed by TRITC-conjugated secondary
antibodies. Filamentous actin was detected with FITC-conju-
gated phalloidin and the cells were examined by immunoﬂu-
orescence microscopy. In non-stimulated cells, DOCK8 was
present in the cytoplasm but an accumulation of DOCK8 in
protrusions at the cell edges, presumably in lamellipodia, was
clearly visible (Fig. 4A). The localisation to lamellipodia in-
Fig. 4. Subcellular localisation of HA-tagged DOCK8. PAE/PDGFRb cells were transiently transfected with HA-tagged DOCK8, the cells were
starved and left non-stimulated (A) or treated with 100 ng/ml PDGF-BB for 10 min (B) or 10% FCS for 5 min (C). HA-tagged DOCK8 was detected
by an HA-speciﬁc mouse anti-HA antibody followed by a tetramethyl rhodamine isothiocyanate (TRITC)-labelled anti mouse antibody. Fila-
mentous actin was detected by Fluorescein isothiocyanate (FITC)-labelled phalloidin. The arrowheads mark the presence of HA-tagged DOCK8 in
lamellipodia of transfected cells. The bar denotes 20 lm.
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(Fig. 4B and C).
Next, PAE/PDGFRb cells were ﬁxed in 3% paraformalde-
hyde and endogenous DOCK8 was visualised with the rabbit
polyclonal DOCK8 antibody. Endogenous DOCK8 was also
found at lamellipodia, thereby conﬁrming the observation with
the transiently transfected HA-DOCK8 (Fig. 5A). DOCK8
was also visualised in NIH3T3 ﬁbroblasts. These cells had very
small lamellipodia, thus the peripheral localisation of DOCK8
was not very prominent (Fig. 5A). If the PAE/PDGFRb cells
instead were ﬁxed in ice-cold methanol, a nuclear staining was
seen in addition to the cytoplasmic staining (Fig. 5B). Pre-in-
cubation of the DOCK8 antibody with the peptide antigen
eﬀectively quenched the signal, indicating that the staining
pattern indeed represented the localisation of the endogenous
DOCK8 (Fig. 5B). A HA-tagged C-terminal fragment of
DOCK8 (DOCK8:1179–1701) was transfected into PAE/
PDGFRb cells. This fragment localised into ring-like struc-
ture, a staining pattern very distinct from the full-length
DOCK8 (Fig. 5C). The DOCK8-induced rings also attracted
ﬁlamentous actin to form ring-like structures (Fig. 5C, detail).When the cells were treated with PDGF-BB, the DOCK8 in-
duced rings persisted, but DOCK8 also relocalised into la-
mellipodia.4. Discussion
The ﬁrst described member of the CDM family of proteins,
DOCK180, was isolated during a search for proteins inter-
acting with the proto-oncogene product c-Crk [17]. The Ca-
enorhabditis elegans DOCK180 orthologue Ced-5 has been
shown to control the engulfment of apoptotic cells as well as
the migration of gonad cells [18]. In Drosophila melanogaster,
the ﬂies harbouring mutations in Myoblast City (Mbc) are
defective in the process that result in the fusion of single cell
myocytes into multinuclear myoblasts. In addition, Mbc mu-
tants are defective in the migration of so-called border cells to
the egg chambers [19]. This process is also dependent on the
PDGF-like ligand PVF [20]. In mammalian cells, recent ob-
servations indicate that DOCK family of proteins is encoded
by at least 11 genes, which can be further divided into 4 sub-
Fig. 5. Subcellular localisation of endogenous DOCK8 and the C-terminal fragment of DOCK8. (A) NIH3T3 and PAE/PDGFRb cells were starved
and ﬁxed in 3% paraformaldehyde. Endogenous DOCK8 was detected with a rabbit polyclonal DOCK8 antibody followed by a TRITC-labelled anti
rabbit antibody. (B) PAE/PDGFRb cells were ﬁxed in ice-cold methanol. Endogenous DOCK8 was detected with a rabbit polyclonal DOCK8
antibody followed by a TRITC-labelled anti rabbit antibody. The speciﬁcity of the DOCK8 antibody was determined by pre-incubating the antibody
with the peptide antigen. The arrowheads mark the presence of DOCK8 in lamellipodia. (C) PAE/PDGFRb cells were transiently transfected with
HA-tagged DOCK8:1179–1701, the cells were starved and then either non-stimulated or treated with 100 ng/ml PDGF-BB for 5 min. HA-tagged
DOCK8 C-terminal was detected by an HA-speciﬁc mouse anti-HA antibody followed by a TRITC-labelled anti mouse antibody. Filamentous actin
was detected by FITC-labelled phalloidin. The bar denotes 20 lm.
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in more detail and most of our current knowledge comes from
studies on the DOCK180 and DOCK2, which have roles in
regulating diﬀerent aspects of cytoskeletal reorganisation
[17,21]. Interestingly, the DOCK180-like modiﬁer of cell ad-
hesion (MOCA), which was originally identiﬁed as a preseni-
lin-binding protein, has been linked to the regulation of
amyloid precursor protein metabolism [22,23]. Apart from
these examples, very little is known about the DOCK family
proteins and, in fact, they share little sequence homology
outside the CZH1 and CZH2 domains. The data presented in
this article suggest that DOCK8 is present in lamellipodia and
other areas undergoing dynamic actin reorganisation. In ad-
dition, a C-terminal fragment of DOCK8, encompassing the
CZH2 domain, was able to induce ﬁlamentous actin-contain-
ing vesicular structures.
In C.elegans, as well as in mammalian cells, DOCK signal-
ling has been shown to involve CrkII, Rac1 and ELMO
[24,25]. Interestingly, DOCK has been shown to trigger GTP-
loading of Rac, through a mechanism that is independent of
the classical Dbl homology domain-containing GEFs [26,27].
Some additional DOCK family members, such as Zizimin, also
activate GTPases (in this case Cdc42) [15]. In contrast, we havenot been able to detect a stable interaction between Cdc42 and
DOCK8 in any of the immunoprecipitation or pull-down ex-
periments performed. In addition, no major inﬂuence of
DOCK8 on the GTP-loaded status of Cdc42 nor of Rac1 was
detected, yet DOCK8 binds Cdc42, TCL, TC10 and Rac1 in
the yeast two-hybrid system with high aﬃnity. To this end, it is
worth noticing that the yeast two-hybrid system will also allow
the detection of very transient interactions. This suggests that a
functional interaction between DOCK8 and Cdc42 is likely to
be transient and that an additional protein, such as ELMO,
might be needed in order to achieve an eﬃcient binding or
exchange activity of DOCK8 [24,25]. ELMO binds to the SH3
domain of DOCK180, a domain absent from DOCK8, making
ELMO a less likely ‘‘stabiliser’’ of a potential DOCK8 ex-
change activity [25]. In addition, the diﬀerence between the
pull-down experiments and the yeast two-hybrid experiments
might be caused by the use of diﬀerent mutants of Rac1 and
Cdc42. In the yeast two-hybrid system, GTPases with muta-
tions in the CAAX box were used, whereas in the pull-down
experiments the CAAX box was intact. Zizimin was shown to
trigger the exchange of a Cdc42 CAAX box mutation with a
signiﬁcantly higher eﬃciency [15]. Hopefully, future studies
will resolve the nature of the DOCK8:Cdc42 interaction.
Fig. 5 (continued)
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